Nasdaq GlobeNewswire

Merus Announces Participation in Four Investor Conferences in February 2018

Del

UTRECHT, The Netherlands, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company's management will participate at four upcoming investor conferences in February, including:

  • BioCapital Europe 2018
    • Mark Throsby, Ph.D., Executive Vice President and Chief Scientific Officer, will present on February 6, 2018 at 3:20 p.m. CET in Amsterdam, The Netherlands.
  • SunTrust Robinson Humphrey's 2018 Orphan Drug Day
    • Hui Liu, Executive Vice President and Chief Business Officer, and John Crowley, Executive Vice President and Chief Financial Officer, will host meetings with investors at the conference on February 13, 2018 in New York City.
  • Leerink Partners' 7th Annual Global Healthcare Conference
    • Ton Logtenberg, Ph.D., Chief Executive Officer, will participate in a fireside chat on February 15, 2018 at 10:00 a.m. ET in New York City.
  • RBC Capital Markets 2018 Global Healthcare Conference
    • Ton Logtenberg, Ph.D., Chief Executive Officer, will participate in a fireside chat on February 22, 2018 at 11:00 a.m. ET in New York City.

A live webcast of Merus' presentations at the Leerink and RBC conferences on will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.

About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and NSCL cancers. Merus' second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation.

Contacts:
Investors:
Kimberly Minarovich 
+1 646-368-8014
kimberly@argotpartners.com

Media:
David Rosen 
+1 212-600-1902
david.rosen@argotpartners.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Bermuda Principles event merges science and business20.2.2018 16:36Pressemelding

HAMILTON, Bermuda, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Scientists and researchers from around the world are gathering in Bermuda this week for the second edition of a conference exploring the field of genetic research. Premier the Hon David Burt will officially open "Bermuda Principles: Impact on Splicing" Wednesday evening at the Fairmont Southampton. The conference, which runs through Saturday, has registered 50 delegates, along with an impressive roster of 36 speakers and panellists from 11 countries, including Australia, Denmark, Switzerland and South Africa. Among the attendees are prominent geneticists, scientists, professors, researchers, PhD students working in international labs, biotech representatives and investors. "I am elated to see the growth of the conference since last year's event," said Bermudian Dr. Carika Weldon, a biomedical researcher with her own lab at De Montfort University, UK, who conceived of the event and launched it last February. "My main aim has been to p

Globecomm Joins Amazon Web Services Partner Network20.2.2018 16:00Pressemelding

Highlights Globecomm establishes direct access to Amazon Web Services (AWS) Direct Connect at key datacenter locations. Customers in U.S. Government, media and entertainment, enterprise video and the Internet of Things (IoT) can interoperate cloud-based services with Globecomm's global satellite and fiber network to reduce capital expenditure and ramp up networks and services faster. Globecomm's suite of Software-as-a-Service (SaaS) applications run on AWS, accessible across both AWS and Globecomm's global network. Globecomm's team in place to design, develop and deliver cloud-centric as well as hybrid architectures for end-to-end services and customer solutions. HAUPPAUGE, N.Y., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Globecomm announced today that it has joined the Amazon Web Services (AWS) Partner Network (APN) as a Standard Technology Partner. This agreement will enable Globecomm to seamlessly interoperate its global satellite and fiber network with AWS's storage, compute and cloud conte

Elite Capital & Co. awarded Infrastructure Project Finance Provider 2018 by New European Economy20.2.2018 15:41Pressemelding

LONDON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- The Information Department at Elite Capital & Co. Limited (ECC), announced today that the company features in the specialized and prestigious New European Economy Magazine in its January 2018 issue in Britain and the European Union countries as the "Infrastructure Project Finance Provider 2018". The award is the result of focused efforts and synergy between the ECC Board of Directors and our employees and strategic partners all over the world over the past years. It also reflects the ability of the Company's strategy to adapt to the prevailing global economic circumstances and testifies to the viability of the planning process adopted by the Board of Directors. Dr. Faisal Khazaal, Chairman of Elite Capital & Co. commented on the occasion, "I should thank Mr. George Matharu, President of ECC and his Board Members who make ceaseless efforts towards ensuring that ECC continues to occupy a prestigious position in the field of finance and economy in

New MindManager 11 for Mac: Visually Capture, Organize, and Share Information to Drive Project and Business Success20.2.2018 15:26Pressemelding

Powerful mind mapping and information visualization software introduces its most robust Mac version yet; complete with new diagram types, an expanded template library, advanced mapping capabilities, and improved sharing options OTTAWA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Introduced today, MindManager® 11 for Mac brings new elegance and efficiency to the way individuals and teams organize ideas, tackle tasks, and achieve their goals. Already a leader in mind mapping and information visualization on the Mac, MindManager's new release offers advanced mapping capabilities, new diagram types and templates, and easy ways to share and publish your work - all delivered within a redesigned interface optimized to enhance productivity. Individuals, small businesses, and global organizations rely upon MindManager to efficiently brainstorm and organize ideas, communicate knowledge effectively, and execute project success. MindManager enables users to turn unstructured ideas and information into dynam

Ovum Survey Finds NetSfere Among The Top 3 Most Widely Deployed Secure Enterprise Messaging Services20.2.2018 15:00Pressemelding

NetSfere is the third most used enterprise platform, clearly outpacing legacy enterprise communication vendors CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- A report by Ovum, a market-leading research and consulting firm, commissioned by Infinite Convergence Solutions, a global leader in messaging and mobility solutions, finds that within just a few short years of launching, NetSfere is ranked as the third most used enterprise messaging service behind Skype Business and Cisco's Spark. In addition to the need for a secure messaging service, the report shows enterprise demand for communication services that enable collaboration beyond messaging. NetSfere's combined HD voice, video and text capabilities - all preferred means of communication in one encrypted platform - validates its ranking among the top services for enterprises. "With messaging services advancing into all-in-one communications platforms, there's a greater propensity for widespread business use - but also major security risk

Inspiration to Seek Shareholder Approval for Forward Split of its Common Shares20.2.2018 15:00Pressemelding

TORONTO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation ("Inspiration" or the "Corporation") (CSE:ISM) would like to announce that, further to its press release dated January 18, 2018, it will be seeking shareholder approval for a special resolution authorizing the directors to effect a forward split of the Corporation's common shares on a one (1) for two (2) basis. As stated in the Corporation's press release of January 18, 2018, Inspiration has scheduled its annual and special meeting of shareholders for May 3, 2018. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This press release contains forward-looking statements based on assumptions, uncertainties and management's best estimates of future events. Actual results may differ materially from those currently antici

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom